Images List Premium Download Classic

Psychiatric

Psychiatric-related patent applications - as published by the U.S. Patent and Trademark Office (USPTO).


loading
Hydroxmethyl piperidine orexin receptor antagonists
Merck Sharp & Dohme Corp.
November 09, 2017 - N°20170320884

The present invention is directed to hydroxymethyl piperidine compounds which are antagonists of orexin receptors. The present invention is also directed to uses of the compounds described herein in the potential treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The present invention is also directed to compositions comprising these compounds. The present ...
Bridged diazepane orexin receptor antagonists
Merck Sharp & Dohme Corp.
November 09, 2017 - N°20170320876

The present invention is directed to bridged diazepane compounds which are antagonists of orexin receptors. The present invention is also directed to uses of the compounds described herein in the potential treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The present invention is also directed to compositions comprising these compounds. The present ...
6,5-bicyclic octahydropyrrolopyridine orexin receptor antagonists
Merck Sharp & Dohme Corp.
November 09, 2017 - N°20170320874

The present invention is directed to 6,5-bicyclic octahydropyrrolopyridine compounds which are antagonists of orexin receptors. The present invention is also directed to uses of the compounds described herein in the potential treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The present invention is also directed to compositions comprising these compounds. The present ...
Psychiatric Patent Pack
Download 117+ patent application PDFs
Psychiatric Patent Applications
Download 117+ Psychiatric-related PDFs
For professional research & prior art discovery
inventor
  • 117+ full patent PDF documents of Psychiatric-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Amidoethyl azole orexin receptor antagonists
Merck Sharp & Dohme Corp.
November 09, 2017 - N°20170320856

The present invention is directed to amidoethyl azole compounds which are antagonists of orexin receptors. The present invention is also directed to uses of the compounds described herein in the potential treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The present invention is also directed to compositions comprising these compounds. The present ...
Pyrazole, triazole and tetrazole orexin receptor antagonists
Merck Sharp & Dohme Corp.
November 09, 2017 - N°20170319560

The present invention is directed to pyrazole, triazole and tetrazole compounds which are antagonists of orexin receptors. The present invention is also directed to uses of the pyrazole, triazole, and tetrazole compounds described herein in the potential treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The present invention is also directed to ...
Piperidine oxadiazole and thiadiazole orexin receptor antagonists
Merck Sharp & Dohme Corp.
November 02, 2017 - N°20170313693

The present invention is directed to piperidine oxadiazole and thiadiazole orexin compounds which are antagonists of orexin receptors. The present invention is also directed to uses of the compounds described herein in the potential treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The present invention is also directed to compositions comprising these ...
Psychiatric Patent Pack
Download 117+ patent application PDFs
Psychiatric Patent Applications
Download 117+ Psychiatric-related PDFs
For professional research & prior art discovery
inventor
  • 117+ full patent PDF documents of Psychiatric-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Xenon and/or argon treatment as an adjunct to psychotherapy for psychiatric disorders
Merck Sharp & Dohme Corp.
November 02, 2017 - N°20170312308

The present invention relates generally to the fields of treating psychiatric disorders, in particular, anxiety disorders including post-traumatic stress disorder (ptsd) in subjects, e. G., human subjects, by administering a xenon and/or argon containing composition. Treatments can also employ psychotherapy in combination with administration of xenon and/or argon, alone or in combination with additional psychotherapeutic medications to treat ...
Systems and methods for generating biomarkers based on multivariate classification of functional imaging and associated ...
The Brigham And Women's Hospital, Inc.
October 26, 2017 - N°20170309022

Systems and methods for generating biomarkers associated with neuropsychiatric disorders, neurodevelopmental disorders, neurobehavioral disorders, or other neurological disorders are described. In general, the biomarkers are generated based on correlations between functional imaging data and clinical acquired from a subject, as computed using a multivariate classifier. Functional imaging data may include functional magnetic resonance images, or activation maps generated from such ...
Methyl diazepane orexin receptor antagonists
Merck Sharp & Dohme Corp.
October 26, 2017 - N°20170305916

The present invention is directed to methyl diazepane compounds which are antagonists of orexin receptors. The present invention is also directed to uses of the compounds described herein in the potential treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The present invention is also directed to compositions comprising these compounds. The present ...
Substituted pyrazoloquinazolinones and pyrroloquinazolinones as allosteric modulators of group ii metabotropic glutamate receptors
Domain Therapeutics
October 26, 2017 - N°20170305913

The present invention provides pyrazoloquinazolinone and pyrroloquinazolinone derivatives of the general formula (i) and pharmaceutical compositions containing them. Moreover, the compounds of formula (i) and the compositions containing them are provided for use in the treatment and/or prophylaxis of conditions associated with altered glutamatergic signalling and/or functions, and/or conditions which can be affected by alteration of glutamate ...
Pro-neurogenic compounds
Board Of Regents Of The University Of Texas System
October 26, 2017 - N°20170305906

Compounds and methods for stimulating neurogenesis (e. G., post-natal neurogenesis, including post-natal hippocampal and hypothalamic neurogenesis) and/or protecting neuronal cell from cell death are disclosed herein. In vivo activity tests suggest that these compounds may have therapeutic benefits in neuropsychiatric and/or neurodegenerative diseases such as schizophrenia, major depression, bipolar disorder, normal aging, epilepsy, traumatic brain injury, post-traumatic stress ...
7,8-dihydoxyflavone and 7,8-substituted flavone derivatives, compositions, and methods related thereto
Board Of Regents Of The University Of Texas System
October 26, 2017 - N°20170305876

Bdnf and trkb activity, such as psychiatric disorders, depression, post-traumatic stress disorder, and autism spectrum disorders, stroke, rett syndrome, parkinson's disease, and alzheimer's disease by administering effective amounts of pharmaceutical compositions comprising compounds disclosed herein to a subject in need thereof. In certain embodiments, it is contemplated that the 7,8-substituted flavone derivatives disclosed herein are prodrugs of 7,8-dihydoxyflavone and analogs.
Systems and methods for treating a psychiatric disorder
Icahn School Of Medicine At Mount Sinai
October 26, 2017 - N°20170303851

Systems and methods for treating a subject with a psychiatric disorder are provided in which a therapy session is conducted. In the therapy session, each respective expression image in a plurality of expression images is sequentially displayed. Each expression image is independently associated with an expression. The successive display of images is construed as a tiled series of expression image ...
Psychiatric Patent Pack
Download 117+ patent application PDFs
Psychiatric Patent Applications
Download 117+ Psychiatric-related PDFs
For professional research & prior art discovery
inventor
  • 117+ full patent PDF documents of Psychiatric-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Thiazolidinones as cellular anandamide uptake inhibitors and their use in the treatment of psychiatric or ...
Icahn School Of Medicine At Mount Sinai
October 19, 2017 - N°20170296515

The invention relates to a compound comprising the following general formula (1) for use in the treatment of psychiatric or neurological disorders and inflammation, in particular neuroinflammation: (1) wherein each of r1, r2 and r3 are selected independently from each other from alkyl, alkoxy, alkenyl, alkynyl, cycloalkyl, aryl, heterocycle or heteroaryl.
Imidazopyrazinones as pde1 inhibitors
H. Lundbeck A/s
October 12, 2017 - N°20170291903

The present invention provides imidazopyrazinones as pde1 inhibitors and their use as a medicament, in particular for the treatment of neurodegenerative disorders and psychiatric disorders.
1,5-dihydro-4h-pyrazolo[3,4-d]pyrimidin-4-ones and 1,5-dihydro-4h-pyrazolo[4,3-c]pyridin-4-ones as pde1 inhibitors
H. Lundbeck A/s
October 12, 2017 - N°20170291901

The present invention provides 1,5-dihydro-4h-pyrazolo[3,4-d]pyrimidin-4-ones and 1,5-dihydro-4h-pyrazolo[4,3-c]pyridin-4-ones of formula (i) as pde1 inhibitors and their use as a medicament, in particular for the treatment of neurodegenerative disorders and psychiatric disorders.
Methods for enhancing permeability to blood-brain barrier, and uses thereof
Academia Sinica
October 05, 2017 - N°20170283493

Disclosed herein is a method of facilitating the delivery of an agent across blood-brain barrier (bbb) of a subject. The method includes administering to the subject in sequence or concomitantly, an effective amount of a growth factor selected from the group consisting of, vascular endothelial growth factor (vegf), insulin-like growth factor i (igf-1), igf-ii, a portion thereof and a combination ...
Dosing regimen for missed doses for long-acting injectable paliperidone esters
Janssen Pharmaceuticals, Inc.
October 05, 2017 - N°20170281629

The present application provides a method for treating patients in need of psychiatric treatment, wherein said patient is being treated with the 3-month formulation of paliperidone palmitate and fails to take the next scheduled dose of the 3-month formulation of paliperidone palmitate.
Use of 4-aminopyridine to improve neuro-cognitive and/or neuro-psychiatric impairment in patients with demyelinating and ...
Acorda Therapeutics, Inc.
October 05, 2017 - N°20170281608

Disclosed herein are methods and compositions related to use of aminopyridines, such as 4-aminopyridine, to improve the neuro-cognitive impairments and related neuro-psychiatric impairments of patients with a demyelinating condition such as ms, traumatic brain injury, cerebral palsy, post-radiation encephalopathy.
4-(3-cyanophenyl)-6-pyridinylpyrimidine mglu5 modulators
Heptares Therapeutics Limited
September 28, 2017 - N°20170275265

The disclosures herein relate to novel compounds of formula wherein r1, r2, r3 and r4 and n are defined herein, and their use in treating, preventing, ameliorating, controlling or reducing the risk of inflammation, neurological or psychiatric disorders associated with modulating mglu5 receptor function.
Quinazolin-thf-amines as pde1 inhibitors
H. Lundbeck A/s
September 21, 2017 - N°20170267664

The present invention provides quinazolin-thf-amines as pde i inhibitors and their use as a medicament, in particular for the treatment of neurodegenerative disorders and psychiatric disorders.
Loading